A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
Conditions: Advanced Solid Tumor

Interventions: Drug: OBI-992

Sponsors: OBI Pharma, Inc

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments